HRP20150623T1 - Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen - Google Patents
Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen Download PDFInfo
- Publication number
- HRP20150623T1 HRP20150623T1 HRP20150623TT HRP20150623T HRP20150623T1 HR P20150623 T1 HRP20150623 T1 HR P20150623T1 HR P20150623T T HRP20150623T T HR P20150623TT HR P20150623 T HRP20150623 T HR P20150623T HR P20150623 T1 HRP20150623 T1 HR P20150623T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- seq
- acid sequence
- antigen
- antibody
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 8
- 102000036639 antigens Human genes 0.000 title claims 8
- 108091007433 antigens Proteins 0.000 title claims 8
- 239000012634 fragment Substances 0.000 title claims 8
- 102000003886 Glycoproteins Human genes 0.000 title claims 2
- 108090000288 Glycoproteins Proteins 0.000 title claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
Claims (10)
1. Protutijelo ili njegov fragment koji se veže na antigen, naznačen/o time, da se specifično veže na glikoprotein gB od humanog citomegalovirusa te koje/koji može neutralizirati njegovo biološko djelovanje, pri čemu
(i) aminokiselinske sekvence od CDR1, CDR2 i CDR3 varijabilnog područja jakog lanca pojedinačno uključuju odnosnim redom:
a) aminokiselinsku sekvencu od SEQ ID NO:13;
b) aminokiselinsku sekvencu od SEQ ID NO:14; i
c) aminokiselinsku sekvencu od SEQ ID NO:15;
i
(ii) aminokiselinske sekvence od CDR1, CDR2 i CDR3 varijabilnog područja slabog lanca pojedinačno uključuju odnosnim redom:
a) aminokiselinsku sekvencu od SEQ ID NO:16;
b) aminokiselinsku sekvencu od SEQ ID NO:17; i
c) aminokiselinsku sekvencu od SEQ ID NO:18.
2. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, naznačen/o time, da obuhvaća:
a) varijabilno područje jakog lanca (HCVR), koje uključuje aminokiselinsku sekvencu od SEQ ID NO:10; i
b) varijabilno područje slabog lanca (LCVR), koje uključuje aminokiselinsku sekvencu od SEQ ID NO:12.
3. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1 ili 2, naznačen/o time, da obuhvaća:
a) jaki lanac (H-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:2 ili 6; i
b) slabi lanac (L-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:4 ili 8.
4. Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 3, naznačen/o time, da obuhvaća:
a) jaki lanac (H-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:6; i
b) slabi lanac (L-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:8.
5. Protutijelo ili njegov fragment koji se veže na antigen prema bilo kojem od zahtjeva 1 do 4, naznačen/o time, da podrazred protutijela je IgG1 λ.
6. Farmaceutski sastav, naznačen time, da obuhvaća protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 5, i farmaceutski prihvatljiv nosač.
7. Vektor, naznačen time, da obuhvaća nukleinsku kiselinu koja kodira aminokiselinsku sekvencu od SEQ ID NO:10, kao i nukleinsku kiselinu koja kodira aminokiselinsku sekvencu od SEQ ID NO:12.
8. Stanica domaćina, naznačena time, da sadrži vektor prema zahtjevu 7.
9. Stanica domaćina, naznačena time, da sadrži vektor koji obuhvaća nukleinsku kiselinu koja kodira aminokiselinsku sekvencu od SEQ ID NO:10, kao i vektor koji obuhvaća nukleinsku kiselinu koja kodira aminokiselinsku sekvencu od SEQ ID NO:12.
10. Postupak proizvodnje protutijela ili njegovog fragmenta koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 5, naznačen time, da obuhvaća korak kultiviranja stanice domaćina prema zahtjevu 8 ili 9.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009089442 | 2009-04-01 | ||
| EP10758877.4A EP2420572B1 (en) | 2009-04-01 | 2010-04-01 | Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof |
| PCT/JP2010/056037 WO2010114106A1 (ja) | 2009-04-01 | 2010-04-01 | ヒトサイトメガロウイルスｇＢ糖タンパク質のＡＤ１領域に存在する特定の不連続エピトープに結合するモノクローナル抗体ならびにその抗原結合性断片 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150623T1 true HRP20150623T1 (hr) | 2015-07-03 |
Family
ID=42828394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150623TT HRP20150623T1 (hr) | 2009-04-01 | 2015-06-10 | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8492529B2 (hr) |
| EP (1) | EP2420572B1 (hr) |
| JP (1) | JP4981192B2 (hr) |
| KR (1) | KR101390015B1 (hr) |
| CN (1) | CN102378814B (hr) |
| AU (1) | AU2010232202B2 (hr) |
| BR (1) | BRPI1013648B1 (hr) |
| CA (1) | CA2756889C (hr) |
| DK (1) | DK2420572T3 (hr) |
| ES (1) | ES2539751T3 (hr) |
| HR (1) | HRP20150623T1 (hr) |
| IL (1) | IL215439A (hr) |
| MX (1) | MX2011010382A (hr) |
| RU (1) | RU2542472C2 (hr) |
| SI (1) | SI2420572T1 (hr) |
| WO (2) | WO2010114105A1 (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201270662A1 (ru) | 2009-12-23 | 2013-01-30 | 4-Антибоди Аг | Связывающие элементы для человеческого цитамегаловируса |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| TW201348247A (zh) * | 2012-05-21 | 2013-12-01 | Abbvie Inc | 利用蛋白質ａ親和性層析之非人類抗體之新穎純化 |
| US20140154270A1 (en) * | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| JPWO2014061783A1 (ja) | 2012-10-19 | 2016-09-05 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CN118465272A (zh) | 2019-12-04 | 2024-08-09 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| RU2738001C1 (ru) * | 2020-03-23 | 2020-12-07 | Борис Сергеевич Першин | Способ определения риска развития цитомегаловирусного (ЦМВ) ретинита после трансплантации гемопоэтических стволовых клеток |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| WO2023039242A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Multivalent interferon particles compositions and methods of use |
| CN114853886B (zh) * | 2022-05-23 | 2023-11-28 | 南昌大学 | 一种高亲和力抗人巨细胞病毒的全人源单克隆抗体及其用途 |
| CN118580343A (zh) * | 2022-10-21 | 2024-09-03 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987003602A1 (en) | 1985-12-06 | 1987-06-18 | Teijin Limited | Anticytomegaloviral human monoclonal antibody and process for its preparation |
| SE9201281L (sv) | 1992-04-23 | 1993-10-24 | Bioinvent Int Ab | Nya humana monoklonala antikroppar och förfarande för framställning därav |
| GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
| US5750106A (en) | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
| WO1994016730A1 (en) | 1993-01-28 | 1994-08-04 | Sandoz Pharmaceutical Corporation | Human monoclonal antibodies to cytomegalovirus |
| JPH0859509A (ja) * | 1994-08-16 | 1996-03-05 | Teijin Ltd | サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤 |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| RU2239453C2 (ru) * | 2002-12-03 | 2004-11-10 | Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" | Препарат иммуноглобулина человека против цитомегаловируса и способ его получения |
| WO2007065433A2 (en) * | 2005-12-05 | 2007-06-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
| WO2007094423A1 (ja) * | 2006-02-15 | 2007-08-23 | Evec Incorporated | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| US8202518B2 (en) | 2007-07-04 | 2012-06-19 | Ribovax Biotechnologies S.A. | Antibodies against human cytomegalovirus (HCMV) |
| WO2009024445A1 (en) | 2007-08-22 | 2009-02-26 | Ribovax Biotechnologies Sa | Antibodies against human cytomegalovirus (hcmv) |
-
2010
- 2010-04-01 KR KR1020117025880A patent/KR101390015B1/ko active IP Right Grant
- 2010-04-01 WO PCT/JP2010/056033 patent/WO2010114105A1/ja active Application Filing
- 2010-04-01 CN CN2010800149887A patent/CN102378814B/zh active Active
- 2010-04-01 DK DK10758877.4T patent/DK2420572T3/en active
- 2010-04-01 BR BRPI1013648-7A patent/BRPI1013648B1/pt active IP Right Grant
- 2010-04-01 CA CA2756889A patent/CA2756889C/en active Active
- 2010-04-01 WO PCT/JP2010/056037 patent/WO2010114106A1/ja active Application Filing
- 2010-04-01 RU RU2011144113/10A patent/RU2542472C2/ru active
- 2010-04-01 JP JP2011507298A patent/JP4981192B2/ja active Active
- 2010-04-01 MX MX2011010382A patent/MX2011010382A/es active IP Right Grant
- 2010-04-01 SI SI201030942T patent/SI2420572T1/sl unknown
- 2010-04-01 US US13/262,061 patent/US8492529B2/en active Active
- 2010-04-01 ES ES10758877.4T patent/ES2539751T3/es active Active
- 2010-04-01 EP EP10758877.4A patent/EP2420572B1/en active Active
- 2010-04-01 AU AU2010232202A patent/AU2010232202B2/en active Active
-
2011
- 2011-09-27 IL IL215439A patent/IL215439A/en active IP Right Grant
-
2015
- 2015-06-10 HR HRP20150623TT patent/HRP20150623T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2539751T3 (es) | 2015-07-03 |
| KR20120035142A (ko) | 2012-04-13 |
| RU2542472C2 (ru) | 2015-02-20 |
| CN102378814A (zh) | 2012-03-14 |
| WO2010114105A1 (ja) | 2010-10-07 |
| JPWO2010114106A1 (ja) | 2012-10-11 |
| CA2756889C (en) | 2017-09-05 |
| IL215439A (en) | 2016-03-31 |
| EP2420572B1 (en) | 2015-03-25 |
| AU2010232202A1 (en) | 2011-10-27 |
| EP2420572A4 (en) | 2013-01-23 |
| CA2756889A1 (en) | 2010-10-07 |
| BRPI1013648B1 (pt) | 2023-05-09 |
| KR101390015B1 (ko) | 2014-04-29 |
| US8492529B2 (en) | 2013-07-23 |
| CN102378814B (zh) | 2013-06-12 |
| MX2011010382A (es) | 2012-01-12 |
| RU2011144113A (ru) | 2013-05-10 |
| US20120093810A1 (en) | 2012-04-19 |
| EP2420572A1 (en) | 2012-02-22 |
| JP4981192B2 (ja) | 2012-07-18 |
| AU2010232202B2 (en) | 2013-08-29 |
| DK2420572T3 (en) | 2015-06-15 |
| IL215439A0 (en) | 2011-12-29 |
| WO2010114106A1 (ja) | 2010-10-07 |
| BRPI1013648A2 (pt) | 2020-09-15 |
| SI2420572T1 (sl) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| HRP20240774T1 (hr) | Anti-il-33 antitijela i njihove upotrebe | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20131167T1 (hr) | Antitijela za humani receptor programirane smrti pd-1 | |
| JP2017052784A5 (hr) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| RU2020120613A (ru) | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения | |
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2020504101A5 (hr) | ||
| JP2013198490A5 (hr) | ||
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| JP2012116856A5 (hr) |